Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment - Takeaways - MDSpire

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment

  • By

  • Heather E. Hsu

  • Sara Lodi

  • Shapei Yan

  • Benjamin J. Bovell-Ammon

  • Paul J. Christine

  • Alyssa S. Tilhou

  • Dana Bernson

  • Patricia Novo

  • Joshua D. Lee

  • John Rotrosen

  • Jane M. Liebschutz

  • Alexander Y. Walley

  • Marc R. Larochelle

  • July 14, 2026

Share

  • 1

    Buprenorphine-naloxone and extended-release naltrexone are FDA-approved medications for opioid use disorder.

  • 2

    Prior studies suggest buprenorphine-naloxone may reduce fatal and nonfatal opioid overdose compared to XR naltrexone.

  • 3

    The X:BOT trial compared buprenorphine-naloxone and XR naltrexone but did not statistically analyze mortality differences.

  • 4

    This study utilized a target trial emulation framework to compare the effectiveness of buprenorphine-naloxone and XR naltrexone.

  • 5

    Outcomes measured included all-cause mortality and nonfatal opioid overdose within 24 weeks of medically managed opioid withdrawal.

Original Source(s)

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment

  • by Heather E. Hsu, Sara Lodi, Shapei Yan, Benjamin J. Bovell-Ammon, Paul J. Christine, Alyssa S. Tilhou, Dana Bernson, Patricia Novo, Joshua D. Lee, John Rotrosen, Jane M. Liebschutz, Alexander Y. Walley, Marc R. Larochelle

  • July 14, 2026

Related Content

Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose

Secretary Kennedy Highlights Eat Real Food and Great American Recovery in Michigan

Adjunctive Psychosocial Interventions and Opioid Abstinence Among Patients Receiving Buprenorphine: A